Comparative efficacy and safety of Evogliptin in type 2 diabetes patients above and below 65 years. Kim J, Kim YS, Hwang YC, Yim JE, et al. Diabetes Obes Metab 2025 Jul 29. doi: 10.1111/dom.16659.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kim J, Kim YS, Hwang YC, Yim JE, et al. Comparative efficacy and safety of Evogliptin in type 2 diabetes patients above and below 65 years. Diabetes Obes Metab 2025 Jul 29. doi: 10.1111/dom.16659.
PMID: 40726428